Oral News and Research

RSS

New meta-analysis highlights significant gaps in hepatitis C care

A new meta-analysis published online in PLOS ONE by infectious disease and epidemiology specialists from the Perelman School of Medicine at the University of Pennsylvania highlights significant gaps in hepatitis C care that will prove useful as the U.S. health care system continues to see an influx of patients with the disease because of improved screening efforts and new, promising drugs.

3 Jul 2014

Isis Pharmaceuticals gets $1 million from GSK to discover and develop drugs for HBV

Isis Pharmaceuticals, Inc. announced today that it has earned a $1 million payment from GlaxoSmithKline related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV).

2 Jul 2014

Genentech agrees to acquire Seragon Pharmaceuticals

Genentech, a member of the Roche Group, today announced it has entered into a definitive agreement to acquire Seragon Pharmaceuticals, Inc., a privately held biotechnology company based in San Diego, California.

2 Jul 2014

NCCN Policy Summit to address impact of health care reform on academic oncology practice

On July 10, 2014, the National Comprehensive Cancer Network® (NCCN®) will host the NCCN Policy Summit: The Impact of Health Care Reform on Academic Oncology Practice, at The Westin Arlington Gateway in Arlington, Virginia, as part of the NCCN Oncology Policy Program.

1 Jul 2014

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

CTI BioPharma Corp. announced today that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis.

From Baxter International Inc. 1 Jul 2014

Herbal supplement can become dangerous when taken with prescribed drugs

St. John's wort, the leading complementary and alternative treatment for depression in the United States, can be dangerous when taken with many commonly prescribed drugs, according to a study by researchers at Wake Forest Baptist Medical Center.

1 Jul 2014

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck, known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years.

30 Jun 2014

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.

30 Jun 2014

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug.

28 Jun 2014

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal, or within 20 minutes after starting a meal.

28 Jun 2014

Non-surgical gum disease treatment reduces thickness of wall of arteries

A simple non-surgical gum disease treatment markedly reduces the thickness of the wall of the arteries, a risk factor for heart disease, according to a first of its kind study among Aboriginal Australians.

28 Jun 2014

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jun 2014

Researchers find way to diagnose aggressiveness of oral cancer

Studying mouth cancer in mice, researchers have found a way to predict the aggressiveness of similar tumors in people, an early step toward a diagnostic test that could guide treatment, according to researchers at Washington University School of Medicine in St. Louis.

28 Jun 2014

EMA CHMP adopts positive opinion for Bristol-Myers Squibb’s Daklinza for HCV treatment

Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.

27 Jun 2014

Auxilium Pharmaceuticals plans to merge with QLT

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, and QLT Inc., a Canadian-based biotechnology company focused on developing innovative orphan ophthalmology products, today announced that they have entered into a definitive agreement under which Auxilium plans to merge with QLT.

26 Jun 2014

Oral gavage is not appropriate for hazard assessments of EDCs, say researchers

Challenging risk assessment methods used for decades by toxicologists, a new review of the literature led by environmental health scientist Laura Vandenberg at the University of Massachusetts Amherst suggests that oral gavage, the most widely accepted method of dosing lab animals to test chemical toxicity, does not accurately mimic how humans are exposed to chemicals in everyday life.

25 Jun 2014

Patients with Cushing’s syndrome experience significant weight loss while taking oral medication

Sinai Hospital of Baltimore endocrinologist, Henry G. Fein, M.D., today presented new research showing that patients with Cushing's syndrome, a rare disease that can lead to extreme weight gain, type 2 diabetes, high blood pressure and psychological issues, experienced significant, sustained weight loss while taking oral medication daily over a number of years to manage symptoms of the disease.

25 Jun 2014

Oral News and Research

New meta-analysis highlights significant gaps in hepatitis C care

Isis Pharmaceuticals gets $1 million from GSK to discover and develop drugs for HBV

Genentech agrees to acquire Seragon Pharmaceuticals

NCCN Policy Summit to address impact of health care reform on academic oncology practice

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

Herbal supplement can become dangerous when taken with prescribed drugs

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Afrezza gets FDA approval to improve glycemic control in adults with diabetes mellitus

Non-surgical gum disease treatment reduces thickness of wall of arteries

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Researchers find way to diagnose aggressiveness of oral cancer

EMA CHMP adopts positive opinion for Bristol-Myers Squibb’s Daklinza for HCV treatment

Auxilium Pharmaceuticals plans to merge with QLT

Oral gavage is not appropriate for hazard assessments of EDCs, say researchers

Patients with Cushing’s syndrome experience significant weight loss while taking oral medication

Journal of the American Dental Association to be published by Elsevier on January 2015

Dental hygienists prepare to take increased responsibilities for oral health care

Small antioxidant molecules suppress colon cancer associated with colitis

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News